Figure 2 | Scientific Reports

Figure 2

From: Expression pattern and clinical significance of β-catenin gene and protein in patients with primary malignant and benign bone tumors

Figure 2

The β-catenin gene expression in malignant bone tumors with different tumor grades, metastasis, recurrent and chemotherapy status. The β-catenin mRNA expression level was evaluated in different types of osteosarcoma, chondrosarcoma, and Ewing's Sarcoma. An increase in the mRNA expression level of β-catenin was observed in chemotherapy-received osteosarcoma and Ewing's Sarcoma tumors (a), osteosarcoma, chondrosarcoma, and Ewing's Sarcoma high-grade tumors (b), recurrent osteosarcoma and Ewing's Sarcoma tumors (c), osteosarcoma and Ewing's Sarcoma tumors with poor response to the chemotherapy (d), and osteosarcoma, chondrosarcoma, and Ewing's Sarcoma metastatic tumors in each malignant group (e). The comparative CT (2−ΔCt) method was applied for gene expression analysis. Kolmogorov–Smirnov analysis showed normal distribution of data therefore t-student test was used to evaluate the difference in the expression level of β-catenin between groups. The statistical differences between groups are shown as asterisk (*P < 0.05, **P < 0.01, ***P < 0.001).

Back to article page